TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BriaCell Therapeutics ( (TSE:BCT) ) just unveiled an update.
BriaCell Therapeutics has announced a collaboration between its subsidiary, BriaPro Therapeutics, and Receptor.AI to develop AI-driven small molecule cancer therapeutics. This partnership aims to expand BriaPro’s small-molecule pipeline and accelerate the development of next-generation therapeutics with improved efficacy and safety, marking a strategic expansion for BriaCell beyond cell-based immunotherapy into small-molecule discovery. The collaboration will leverage Receptor.AI’s platform to design highly selective anti-cancer kinase inhibitors, enhancing precision and confidence in oncology programs.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$40.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care. Its subsidiary, BriaPro Therapeutics Corp., is a pre-clinical stage company working on binding agents and proteins to enhance the body’s cancer-fighting capabilities.
Average Trading Volume: 4,252
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$19.03M
For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.